A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease worsened after initial response to immunotherapy. The randomized phase II study, known as HCRN LUN15-233, involves Taxotere® with or without Opdivo®. About 58 subjects will participate in the study, and will be randomized to one of two treatment arms. Arm A will receive Taxotere plus Opdivo, while Arm B will receive Opdivo alone. Eligible subjects must have advanced non-squamous non-small cell lung cancer with previous clinical benefit on treatment with single agent Opdivo. Additional criteria must be met to enroll. Learn more at http://hoosiercancer.org/clinical-trials/trial/lun15-233/.